biostudies-literatureUnknown64(SI)Velauthapillai AFoundation for Research in RheumatologyScleroderma Clinical Trials ConsortiumScleroderma Research FoundationWellcome Trust<h4>Background</h4>Hypothesizing that early treatment yields improved prognosis, we aimed to investigate how the timing of immunosuppressive treatment relates to interstitial lung disease (ILD) development and the course of pulmonary function in systemic sclerosis (SSc).<h4>Methods</h4>A cohort was created using data from the EUSTAR database and Nijmegen Systemic Sclerosis cohort, including adult patients who started their first immunosuppressive treatment (i.e. mycophenolate mofetil, methotrexate, cyclophosphamide, tocilizumab or rituximab) after SSc diagnosis, and no signs of ILD on high-resolution CT. ILD-free survival and the course of forced vital capacity (FVC) % predicted were assessed for up to 5 years' follow-up comparing patients who started early (disease duration ≤3 years) vs lRheumatology (Oxford, England)SI122-SI130https://www.ebi.ac.uk/biostudies/studies/S-EPMC12695046biostudies-literaturePreventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis.PMC12695046Distler OZhang LNaffaa MMontecucco CDel Papa NVonk MFoti RSpierings JSzucs GDenton CMartin MVanthuyne MMartin TGiacomelli RMouthon LRiccieri VKastrati KGheorghiu AMWalker UBruni CAllanore YBergmann CMatucci-Cerinic MBenvenuti FRiemekasten GMitrovic JKuwana MBrigante JALitinsky IFurst DMaglio CStamenkovic BCantatore FPBecvar RLimonta MIdolazzi LRezus Ede Vries-Bouwstra JMosca MDel Galdo FMukuchyan VKaradag DTPerdan-Pirkmajer KSimeon-Aznar CPMuller-Ladner USfikakis PMiedany YSenet PIudici MCordeiro ACzirjak LMaurer BRosato ESelvi EEUSTAR CollaboratorsKotyla PBootsma MFRBoleto GEpis OMMoroncini GCarreira PEHunzelmann NBalbir-Gurman AMogensen MAlegre-Sancho JJCutolo MGinosyan KAiro PHenes JSolanki KVonk MCZanatta EAnic BGeroldinger-Simic MDe Angelis Rvan den Ende CHMGuiducci STruchetet MELaunay DRednic SLescoat AHinchcliff MGarzanova LInanc MSantos CISCastellvi IAnanieva LPRabaneda EVChatelus EMarcoccia ACuomo GIannone FKrasowska DParvu MBatalov AGyorfi AHBalanescu ARamazan AMIwata FVelauthapillai ADe Santis MChung LSFoeldvari IHaroyan AColic JVardanyan VNunez LMLSmith VDzhus MWojteczek Ada Silva JAPCauli AfalsePreventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis.<h4>Background</h4>Hypothesizing that early treatment yields improved prognosis, we aimed to investigate how the timing of immunosuppressive treatment relates to interstitial lung disease (ILD) development and the course of pulmonary function in systemic sclerosis (SSc).<h4>Methods</h4>A cohort was created using data from the EUSTAR database and Nijmegen Systemic Sclerosis cohort, including adult patients who started their first immunosuppressive treatment (i.e. mycophenolate mofetil, methotrexate, cyclophosphamide, tocilizumab or rituximab) after SSc diagnosis, and no signs of ILD on high-resolution CT. ILD-free survival and the course of forced vital capacity (FVC) % predicted were assessed for up to 5 years' follow-up comparing patients who started early (disease duration ≤3 years) vs l2025-01-01T00:00:00Z2025 Dec2026-06-06T00:36:41.147Z2026-05-24T03:12:12.561ZS-EPMC126950463903791710.1093/rheumatology/keae375